Scpharmaceuticals Inc   (SCPH)
Other Ticker:  
Price: $6.1200 $0.10 1.661%
Day's High: $6.28 Week Perf: 2.17 %
Day's Low: $ 5.98 30 Day Perf: 24.9 %
Volume (M): 122 52 Wk High: $ 12.75
Volume (M$): $ 744 52 Wk Avg: $7.59
Open: $6.03 52 Wk Low: $4.63

 Market Capitalization (Millions $) 237
 Shares Outstanding (Millions) 39
 Employees 2,191
 Revenues (TTM) (Millions $) 8
 Net Income (TTM) (Millions $) -50
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 0

Scpharmaceuticals Inc
SCPharmaceuticals Inc. is a pharmaceutical company that specializes in the development of innovative, simple, and convenient therapies for patients with acute and chronic conditions that require frequent injections or infusions. The company was founded in 2013 and is headquartered in Burlington, Massachusetts, with additional locations in Rhode Island and California.

The primary goal of SCPharmaceuticals is to revolutionize the way patients receive medications by providing them with easy-to-use, portable, and cost-effective options that can be administered outside of traditional healthcare settings. The company's product portfolio includes the Furoscixe (furosemide injection) platform, which is a subcutaneous infusion system designed for patients who require diuretic therapy for heart failure.

Furoscixe is a portable and convenient infusion system that enables patients to self-administer furosemide at home, thereby reducing the need for repeated hospitalizations and improving patient outcomes. The product has demonstrated significant clinical benefits in multiple Phase III clinical trials, including reduced hospitalizations, improved quality of life, and a lower risk of adverse events.

SCPharmaceuticals is also developing other innovative products for the treatment of various conditions, including infectious diseases, metabolic disorders, and inflammatory diseases. The company's pipeline includes several promising candidates, such as the Antibiotic Site Infusion System (ASIS) platform, which is a novel, easy-to-use infusion system for delivering antimicrobial agents to patients with bacterial infections.

Overall, SCPharmaceuticals is dedicated to providing patients with effective, convenient, and affordable therapies that improve their quality of life and reduce the burden of chronic diseases. With its innovative products and commitment to patient-centered care, the company has become a leader in the field of subcutaneous drug delivery and is poised for continued growth and success in the years ahead.

   Company Address: 25 Burlington Mall Road Burlington 1803 MA
   Company Phone Number: 517-0730   Stock Exchange / Ticker: NASDAQ SCPH
   SCPH is expected to report next financial results on March 21, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Scpharmaceuticals Inc

Scpharmaceuticals Inc Generates $3.796 Million in Revenue in Third Quarter, Faces Net Shortfall in Earnings

Scpharmaceuticals Inc Reports Revenue of $3.796 Million in Third Quarter, Faces Net Shortfall in Earnings
Investors showed concern as Scpharmaceuticals Inc, a renowned pharmaceutical company, recently disclosed its third-quarter earnings for 2023. The quarter saw the company generate $3.796 million in revenue, providing some relief amid a challenging market environment. Despite this positive revenue figure, Scpharmaceuticals Inc faced a net shortfall of $-15.634 million, surpassing last year's deficit of $-10.162 million.
The larger net shortfall indicates that Scpharmaceuticals Inc has encountered significant setbacks, potentially impacting its overall financial performance. This shortfall may have been influenced by various factors, such as increased operational costs or unforeseen market challenges. These results have led to speculation among investors about the company's future prospects.

Scpharmaceuticals Inc

Scpharmaceuticals Inc Reveals Impressive Q2 2023 Revenue of $1.638 Million

In the second quarter of the 2023 earnings season, SCPHarmaceuticals Inc (SCPH) reported revenue of $1.638 million, surpassing market expectations. However, the company also revealed a net deficit of $-14.154 million during the same period, a larger deficit compared to the previous year. These financial results highlight the challenges faced by SCPH in recent times. Let's dive deeper into the context of these results and evaluate SCPH's current market performance.
Financial Snapshot
Despite the positive revenue figure, the net deficit reported by SCPH during the second quarter of 2023 paints a less optimistic picture. The $14.154 million net deficit is significantly higher than the $9.697 million net deficit experienced during the same period the previous year. This indicates that the company has struggled to achieve profitability and manage its expenses effectively. SCPH's financial management will require careful scrutiny to reduce the growing deficit.

Scpharmaceuticals Inc

Scpharmaceuticals Inc Reports $2.063 Million in Revenue for Fiscal Period Ending March 31, 2023

Scpharmaceuticals Inc Reports Financial Results for Fiscal Period Ending March 31 2023
Scpharmaceuticals Inc (SCP) has recently released its financial results for the fiscal period ending March 31, 2023. The company reported a revenue of $2.063 million. However, it also realized a net shortfall of $-11.210 million, which is a bigger loss than $-7.731 million in the same period a year ago. This figure shows that the company's expenses were higher than their revenues, leading to a significant net loss.
SCP is a biopharmaceutical company that specializes in developing and commercializing pharmaceutical products for the treatment of cardiovascular diseases. The company's lead product, Furoscix, is a subcutaneous infusion for the outpatient treatment of worsening heart failure. SCP plans to commercialize Furoscix and expand into other cardiovascular disease areas.


Scpharmaceuticals Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com